Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial.
Chevalier B, Di Mario C, Neumann FJ, Ribichini F, Urban P, Popma JJ, Fitzgerald PJ, Cutlip DE, Williams DO, Ormiston J, Grube E, Whitbourn R, Schwartz LB; ZoMaxx I Investigators. Chevalier B, et al. Among authors: ormiston j. JACC Cardiovasc Interv. 2008 Oct;1(5):524-32. doi: 10.1016/j.jcin.2008.08.010. JACC Cardiovasc Interv. 2008. PMID: 19463354 Free article. Clinical Trial.
First-in-human experience with the Medtronic Bifurcation Stent System.
Meredith IT, Worthley S, Whitbourn R, Webster M, Fitzgerald PJ, Ormiston J. Meredith IT, et al. Among authors: ormiston j. EuroIntervention. 2011 Oct 30;7(6):662-9. doi: 10.4244/EIJV7I6A108. EuroIntervention. 2011. PMID: 21959379 Free article. Clinical Trial.
A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimus- vs. Paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: five-year results from the ZOMAXX I trial.
Chevalier B, Dimario C, Neumann FJ, Cutlip DE, Williams DO, Ormiston J, Grube E, Whitbourn R, Coe J, Schwartz LB; ZOMAXX I Investigators. Chevalier B, et al. Among authors: ormiston j. Catheter Cardiovasc Interv. 2013 Dec 1;82(7):1039-47. doi: 10.1002/ccd.24958. Epub 2013 Jul 25. Catheter Cardiovasc Interv. 2013. PMID: 23592567 Clinical Trial.
Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent.
Onuma Y, Serruys PW, Gomez J, de Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia H, Ormiston JA; ABSORB Cohort A and B investigators. Onuma Y, et al. Among authors: ormiston ja. Catheter Cardiovasc Interv. 2011 Jul 1;78(1):3-12. doi: 10.1002/ccd.22864. Epub 2011 Mar 16. Catheter Cardiovasc Interv. 2011. PMID: 21413120 Clinical Trial.
Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y, Serruys PW, Muramatsu T, Nakatani S, van Geuns RJ, de Bruyne B, Dudek D, Christiansen E, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Garcia-Garcia HM, Veldhof S, Rapoza R, Ormiston JA. Onuma Y, et al. Among authors: ormiston ja. JACC Cardiovasc Interv. 2014 Dec;7(12):1400-11. doi: 10.1016/j.jcin.2014.06.016. JACC Cardiovasc Interv. 2014. PMID: 25523532 Free article. Clinical Trial.
257 results